Science.Online
Publisher and Institutes
Akademie Verlag
Deutsches Institut für Urbanistik
Oldenbourg Wissenschaftsverlag
Walter de Gruyter
Schattauer
You are here: Home :: Area NEM :: Medical science :: Human medicine
 
Darja Herman, Polona Peternel, Mojca Stegnar, Katja Breskvar, Vita Dolzan

The influence of sequence variations in factor VII, -glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

Keywords: Polymorphism, warfarin, cytochrome P450 2C9, pharmacodynamic factors, regression model

The degree of interpatient variability in the warfarin dose required to achieve the desired anticoagulant response can only partly be explained by polymorphisms in the CYP2C9 gene, suggesting that additional genetic factors such as polymorphisms in genes involved in blood coagulation may influence warfarin dose requirement. In total, 165 Caucasian outpatients on stable maintenance warfarin treatment previously genotyped for CYP2C9 were analysed for common polymorphisms in FVII, GGCX and VKORC1 genes. The 402G > A polymorphism and a variable number of repeats in intron 7 of FVII gene did not significantly influence warfarin dose. The mean warfarin doses increased with the number of (CAA) repeats in the GGCX gene, but the differences were significant only in the CYP2C91/1 subgroup of patients (p = 0.032). Common polymorphism (6484C > T) in intron 1 of the VKORC1 gene led to lower warfarin dose requirement; the means were 5.70 (95% C.I. 4.956.45), 3.49 (3.073.90) and 2.11 (1.802.42) mg/day for 6484 CC, CT and TT genotypes, respectively (p < 0.001). In contrast, 9041G > A polymorphism in 3UTR of theVKORC1 gene led to higher warfarin dose requirement; the means were 3.09 (2.58 3.60), 4.26 (3.694.82) and 5.86 (4.537.19) mg/day for 9041 GG, GA andAA genotypes, respectively (p < 0.001). With a regression model we explained 60.0% of variability in warfarin dose, which was due to gene polymorphisms (CYP2C9, VKORC1), age and body-surfacearea. When aiming for individualised warfarin therapy, at least VKORC1 polymorphisms should be included in predictive genotyping besides CYP2C9.

Thrombosis and Haemostasis, Schattauer

Print ISSN: 0340-6245
Volume: 95, 05/2006
Pages: 782 - 787

Show full article (external site)

Show all available items of this journal